Group items tagged

NHS England has announced a phased implementation for mandatory multi-sector rotations in the Foundation Pharmacist Training Programme, delaying the full rollout to the 2027/28 training year. Under the General Pharmaceutical Council's Standards for Initial Education and Training of Pharmacists (2021), multi-sector rotations - where trainees spend at least 13 weeks in a different pharmacy setting- were initially planned for all trainees starting in 2026/27. These rotations are designed to enhance pharmacists' adaptability, multi-professional collaboration, and ability to deliver person-centred care across healthcare systems. Acknowledging significant progress from pharmacy employers in developing these programmes, NHS England cited current workforce pressures as a key reason for introducing a phased approach. "We are mindful of the current pressures faced by pharmacy teams and the broader healthcare sector and greatly appreciate your continued commitment to delivering high-quality training. To support pharmacy teams in continuing to deliver high quality training, mandatory rotations will be delayed, and a phased approach will be implemented," David Webb, chief pharmaceutical officer for England and Samantha Illingworth, director of education quality and reform at NHS England, wrote in a letter to training programme providers.

Trust leaders involved in the New Hospital Programme (NHP) have warned that further delays in the government scheme will lead to more patient harm, disappointment among staff, and higher costs for taxpayers. According to NHS Providers, delays in the government scheme that promised 40 new hospitals in England by 2030 are draining millions of pounds from scarce NHS funds every month. Some trusts are compelled to spend over £1 million a month from their under-pressure budgets due to spiraling cost pressures, on-hold building projects, and the bill for having to patch up deteriorating sites. While there has been some progress over the past year, trust leaders remain apprehensive that "uncertainty over funding and shifting timetables risks putting their promised buildings further out of reach."

Health and Social Care Secretary Wes Streeting has on Wednesday laid out his vision for reforming the National Health Service, stating that the NHS is "broken but not beaten" after years of Conservative governance. In his address to the annual Labour Party conference in Liverpool, Streeting highlighted the current challenges facing the NHS, including record-high waiting lists, ambulance delays, and difficulties in accessing GP appointments. Stressing that "reform or die" is the choice facing the NHS, he rejected the idea of simply increasing funding without systemic changes. Streeting noted some initial successes since Labour took office, including employing 1,000 more GPs and negotiating an end to junior doctors' strikes. He revealed that crack teams of top clinicians will be deployed to hospitals across the country to roll out reforms: to treat more patients and cut waiting lists.

Expressing apprehension over the concerning decline in the nursing workforce, Sir Julian Hartley, CEO of NHS Providers, urged the forthcoming government to bolster investment in nursing education and enhance support for student nurses. Recent analysis from the Royal College of Nursing (RCN) has projected that the NHS Long Term Workforce Plan will fall short by 10,000 new nurses by 2025. Commenting on the RCN analysis, Sir Hartley underscored the critical importance of having an adequate number of nurses to ensure the delivery of safe, high-quality patient care. "Without enough nurses, the delivery of safe, high-quality patient care is compromised," he said. He cautioned that the predicted shortfall in nurses would exacerbate existing pressures on the NHS, resulting in long waiting times, delayed treatments and staff burnout.

"Not improving our funding is not an option, if they want to continue to deliver anything like the level of patient care we have done in recent years," he emphasised as he prepares for the NPA'S Save Our Pharmacies Day of Action (June 20). Over the past two years, McElrea has navigated crises stemming from NHS Scotland policies, particularly concerning medicines price inflation and delayed payments. "The cost of medicines increased rapidly compared to inflation," McElrea stated, noting NHS Scotland's slow response in adjusting tariff prices. "This wiped out £50,000 of cash reserves and forced us into £30,000 of additional borrowings." Delayed payments further strained operations, with McElrea highlighting the impact of payments based on outdated pricing.

The Royal Pharmaceutical Society (RPS) in England and 19 other organisations have written to health secretary Wes Streeting, calling for a cohesive cross-government strategy to tackle medicine shortages across the UK. The letter stresses the need for actions to build supply chain resilience, support UK manufacturing, improve data connectivity, protect access to life-critical medicines, and reduce duplication across the NHS. As the government works on its 10-Year NHS Plan, the signatories emphasise the importance of ensuring patients' continued access to vital medicines, which are "an investment in their health." They underscore that the strategy would require engagement by the government across the NHS and the whole of the medicines supply chain, including manufacturers, suppliers, health professions, and patients. The letter also highlights that delays in accessing medicines could be reduced by changing legislation to empower community pharmacists to make minor amendments to prescriptions when shortages occur.

The Association of the British Pharmaceutical Industry (ABPI) has laid out a series of urgent actions it wants the newly elected Labour government to implement within its first 100 days in office. Among the top priorities, the ABPI has emphasised the urgent need to appoint a new Chair and Chief Executive for the Medicines and Healthcare products Regulatory Agency (MHRA). Additionally, the ABPI has urged the new government to launch the Life Sciences Manufacturing Capital Grants Facility without delay. Other measures the ABPI wants Labour to prioritise include: Rapidly passing outstanding UK clinical trials legislation to enhance the UK's attractiveness for inward investment, including into research within the NHS. Increasing commercial flexibility in the NHS England Commercial Framework for New Medicines to remove barriers for companies to launch new medicines and indications so that NHS patients can access the latest innovative medicines.

NHS England has launched the first major update to the 'Act FAST' campaign since 2009, as new data reveals that many stroke patients wait almost an hour and a half on average before making an emergency call. The updated campaign urges the public to call 999 immediately if anyone experiences one of the three common stroke symptoms: difficulty smiling (Face), trouble raising an arm (Arms), or slurred speech (Speech). Around 100,000 people are estimated to suffer a stroke each year in the UK, which occurs when the blood supply to part of the brain is cut off. Without prompt treatment, a stroke can lead to death or long-term disabilities such as paralysis, memory loss and communication problems. Strokes remain the fourth single leading cause of death in the UK, resulting in about 38,000 deaths each year. An analysis of NHS data for 2023-24 indicated that among 41,327 patients with a recorded time of symptom onset, the average time from the first symptom to making a 999 call was 88 minutes. Additionally, a poll of 2,001 adults in England revealed that 57 per cent of respondents believed you should have 2-3 symptoms of a stroke before calling 999, despite the fact that even one symptom is a sign of a medical emergency.

Long appointment wait times, embarrassment, and lack of trust are causing thousands of Brits to avoid visiting doctors, according to new research by Newfoundland Diagnostics. With 1 in 4 individuals resorting to A&E due to the lack of available GP appointments, which adds to the NHS burden, the medical self-testing brand believes that educating the nation on at-home testing can help ease the strain on the health service. The research revealed the top five reasons why Brits avoid visiting doctors for medical testing: Appointments taking too long to book (28 per cent) Embarrassment around their illnesses (15 per cent) Preference for at-home testing (12 per cent) Not having time (10 per cent) Lack of trust in the NHS or their GP (7 per cent) The research team cautioned that delaying care can worsen conditions, resulting in more severe cases that place greater strain on the NHS.

The growing issue of medicine shortages is posing significant challenges for both patients and pharmacy teams across the UK. According to new data from the Office for National Statistics, 20 per cent of adults who used pharmacy prescription services in the last 28 days experienced delays in receiving their medications. The survey, Experiences of NHS healthcare services in England, revealed that over 13 per cent of patients had to return to the same pharmacy at a later time to obtain their prescriptions. Many patients were forced to visit multiple pharmacies or seek alternative services such as a GP or urgent care due to medicine shortages. Pharmacy teams were added with extra burden to manage and resolve these issues. Despite these challenges, 85 per cent of patients expressed satisfaction with pharmacy services, reflecting the dedication and value of pharmacists and pharmacy teams in the community.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved lecanemab (Leqembi) for use in the early stages of Alzheimer's disease, following a thorough review of the drug's benefits and risks. Developed by Japanese pharmaceutical company Eisai, lecanemab is the first treatment for Alzheimer's disease licensed for use in Great Britain, with evidence indicating its potential to slow the disease's progression. Although the MHRA has granted a product license for the medicine, there are concerns about its cost and the potential delay before it becomes accessible to NHS patients. Pharmacist Thorrun Govind told Talk TV that the National Institute for Health and Care Excellence (NICE) is expected to make a final decision on its cost and availability by the end of the year. She highlighted that the drug is currently approved for private use, and that NICE will next evaluate it, weighing patient care against the value for taxpayers, with a final decision expected later this year.

At the Covid Inquiry on Tuesday, Sir Chris Wormald, permanent secretary at the Department of Health and Social Care (DHSC), was questioned about the initial exclusion of community pharmacies in the government's emergency pandemic life assurance scheme. Earlier this month, the National Pharmacy Association (NPA) submitted evidence to the inquiry highlighting the delay in including community pharmacies in the scheme - which offered £60,000 lump sum payments to NHS and care home staff who died from Covid. The inquiry heard that the scheme was launched on April 27, 2020, initially covering NHS and care home staff. However, then Health Secretary Matt Hancock only confirmed the inclusion of community pharmacy staff in a Tweet three days later, on April 30. NPA Chair Nick Kaye told the inquiry that it was "demoralising and demotivating" to community pharmacy staff who worked throughout the pandemic. Jacqueline Carey KC, Counsel to the Covid Inquiry, put the charge to Sir Wormald as he gave evidence about the department's response to the pandemic.

The National Pharmacy Association (NPA) has called on the NHS and the Department of Health to immediately publish the government-commissioned analysis of pharmacy underfunding and reveal the true scale of the crisis. Commissioned by NHS England, the long-awaited independent review is expected to "lay bare the perilous financial state" of community pharmacies, which is a vital part of the nation's health infrastructure. However, the NPA is concerned that the government may delay its release until after current funding consultations are concluded. The NPA argued that the public needs to understand the fragile nature of the pharmacy network before any new deal can be agreed. It has also warned health officials not to hide "the true scale of funding needed to reverse a decade of swingeing cuts", which has forced record numbers of pharmacy closures. NPA chair Nick Kaye said: "It would be a scandal to keep that evidence buried secret and leave MPs, pharmacies and the public in the dark." He acknowledged that the new government has inherited a crisis in pharmacy funding and emphasised that it will need to take "strong action" to maintain access to medicines.

A harsh funding regime that hasn't adapted to changing macroeconomic realities means the viability of large parts of the pharmacy sector is at risk unless the model changes. Very simply, across the sector, revenue has remained largely fixed while costs have increased significantly, making it impossible for many pharmacies to sustain their business models. The sector has seen the closure of more than 1,500 community pharmacies since 2015, with 700 of these closures occurring since 2021. Larger pharmacy operators such as Lloyds, Boots, and Rowlands have seen the biggest decline in numbers, with smaller businesses operating between one and five pharmacies now accounting for almost 50% of the sector. Despite rising inflation and business costs, the NHS pharmacy funding model has remained fixed. Over the period of the current Community Pharmacy Contractual Framework (CPCF) - 2019-2024 - pharmacies have experienced a 30% real terms cut in core funding leading to an annual shortfall of over £750 million, equivalent to £67,000 per pharmacy in England. The current CPCF is due to end in 2024, and there is still no arrangement in place for future funding, leading to delayed and inefficient spending decisions and hampering the ability of the sector to plan and attract much-needed investment.

Major health, care and research bodies, including the Department of Health and Social Care and the Office for National Statistics, should establish a national health data service in England to improve patient care and research - an NHS-commissioned review has recommended. Professor Cathie Sudlow's independent review of the UK health data landscape concluded that "complex and inefficient" data systems prevent and delay crucial analysis of health conditions affecting millions of people across the UK. The review - 'Uniting the UK's health data: a huge opportunity for society', published on 8 November 2024 - stressed the need for coordinated action across multiple organisations and stakeholders to ensure the greatest benefits for patients and the public from health-relevant data. They identified several barriers to using health data for public benefit and set our five recommendations for overcoming these barriers and transforming the national health data ecosystem. These include the establishment of a national health data service for England, embedded within existing organisational structures but with accountable senior leadership and a ring-fenced budget. Professor Sudlow said: "We are simply not maximising the benefits to society from the rich abundance of health data in the UK.

Community pharmacy is stuck in a vicious circle. Pharmacies are closing at an alarming rate whilst the government is talking about moving care away from hospitals and into the community to focus on preventative care. While the government talks about this vision for the future, the stark reality is that pharmacies are already struggling to meet the current Pharmacy First thresholds. And now we discover that one of the key components that could create capacity in pharmacy to deliver more clinical services has been put on hold…indefinitely. The recently published Darzi review, which was commissioned after the new government came to power to assess the state of the NHS, praised the value of community pharmacies and preventative services. But it recognised the level of pharmacy closures across the country and warned pharmacy access could be 'at risk'. Community pharmacy is ideally placed to deliver the government's vision of preventative care in the community. But let's all be clear, moving preventative services into community pharmacies has, so far, been nowhere near as successful as it could have been due to the current climate pharmacies find themselves in. The Pharmacy First scheme is a testament to this. Just this week it was announced that consultation thresholds for the Pharmacy First scheme have been reduced from 30 consultations to 20. It's the second time in three months that the thresholds have been reduced and it follows an intervention from Community Pharmacy England who wanted to "save many pharmacies from missing out on a vital payment this month." In June alone, 3,269 participating pharmacies failed to meet the threshold - that's almost a third of all community pharmacies in England.

Pharmacy owners will be given additional time to claim for the provision of four services if IT issues, outside their control, prevent timely submissions. Effective February 2025, this provision applies to Hypertension Case-Finding, Pharmacy Contraception Service, Pharmacy First, and Smoking Cessation Services. Currently, claims must be submitted via the Manage Your Service (MYS) portal by the 5th of the following month, with late claims accepted only within three months of the actual submission date. Under the new rule, pharmacy owners will have an additional twelve months (from the date by which the claim should have been submitted) to claim payment if they can provide evidence of an IT issue beyond their control that delayed the claim submission. This new provision will be included in Part VIC of the February 2025 Drug Tariff, which will also have a clarification about de-registration from the four advanced services. The clarification will state that pharmacy owners who de-register from providing one of these services cannot re-register for four months after their 30-day notice period ends.

The UK's performance in hospital-based care is falling behind other high-income countries, according to a new report published by the Health Foundation. For hospital care waiting times, the UK ranked among the worst in a public survey of 10 nations, with 11 per cent of people waiting a year or more for a specialist appointment and 19 per cent facing the same delay for non-emergency surgery. Only Canada had comparable figures. The report published on Thursday (22 August) also pointed out that waiting times for specialist appointments have increased more rapidly in the UK than in other countries. In 2023, 61 per cent of people in the UK reported waiting more than four weeks for a specialist appointment, a significant rise from just 14 per cent in 2013. Over 21,000 people from across 10 developed countries, including over 3,000 from the UK, participated in the 2023 Commonwealth Fund survey.

Sector leaders have welcomed the NPA ballot results, which demonstrate that community pharmacies are prepared to take collective action if a funding increase is not achieved. Nearly all pharmacy owners, who participated in the NPA ballot, said they were willing to limit their services to protest funding cuts. Commenting on the poll results, Malcolm Harrison, CEO of the Company Chemists' Association (CCA) said: "The results of the NPA ballot serves to underline the huge pressure that pharmacy contractors face, following a decade of underfunding. He emphasised the need to start the Community Pharmacy Contractual Framework (CPCF) renegotiations for 2024/25 without delay. "The government and NHS must uplift all elements of the contractual framework, to stop further reductions in pharmacy opening hours and permanent pharmacy closures, and to ensure that patients can continue to receive the medicines and clinical care and advice they need," he added. Harry McQuillan, Chairman of Numark, stated that while the NPA ballot outcome has once again brought the financial crisis facing the sector into focus, this is "an everyday reality" for many independent pharmacies and that it has reached "breaking point." He warned that rising operational costs including the increase in national insurance and minimum wage will push many more to the brink.

Pharmacy hub and spoke providers gathered at Westminster on Tuesday (November 19) to highlight to MPs the urgent need to implement Model One of Hub and Spoke legislation. This proposed model, aimed at making hub and spoke dispensing accessible to all pharmacies, was initially scheduled for rollout in January 2025, but has been delayed. Representatives from Centred Solutions, HubRx, and PillTime engaged with over 30 MPs at the event, which was organised with the support of former pharmacist and Labour MP Sadik Al-Hassan. They highlighted the significant benefits of hub and spoke for community pharmacies and stressed the need to extend its use across different legal entities. Sadik Al-Hassan, MP for North Somerset and officer for the Pharmacy APPG, expressed his support, saying, "Community pharmacies are a vital lifeline for our high streets and independents have always been at a disadvantage versus larger chains who can employ economies of scale. "Model One of the proposed legislation would allow the benefits of big pharmacies for smaller ones to help them focus on the service provision our NHS needs during this difficult financial time."